Novel cell therapy may improve heart failure symptoms: Study Shows

▴ Novel cell therapy may improve heart failure symptoms: Study Shows
The cutting-edge treatments for heart failure that may be a good option for these patients

The COVID-19 pandemic has left many people with serious medical conditions, such as heart failure, feeling fearful about coming into the hospital for treatment. A recent study showed a 40 per cent drop in patients seeking medical care for serious heart attacks over the last few months. If left unaddressed, the condition may turn into heart failure, which may limit treatment options even further. Doctors are urging patients not to delay treatment.The good news is that clinical trials for heart disease are underway, studying cutting-edge treatments for heart failure that may be a good option for these patients.

One such treatment being studied uses a patient’s own cells to promote healing of the heart after a heart attack that has progressed to heart failure. The CardiAMP cell therapy is designed for patients suffering from heart failure who feel tired and breathless despite taking regular medications, and who have had to limit their everyday activities as a result. Previously published studies of this type of cell therapy have shown meaningful and sustained improvements in quality of life and heart function for patients with few risks.

"Heart failure patients who continue to have symptoms despite a course of optimal medications often seek a minimally invasive treatment as an alternative to open heart surgery. We look forward to studying the potential of this cell therapy to improve heart function and quality of life," said Dr Natasha Altman, cardiologist and principal investigator of the CardiAMP Heart Failure Trial at UC Health University of Colorado Hospital.

For the treatment, doctors extract cells from a patient’s own bone marrow, process them at the point of care and deliver them to the damaged area of the heart in a minimally invasive cardiac catheterization procedure. Researchers emphasize that the bone marrow cells do not turn into new heart tissue cells; instead, they are designed to stimulate the body’s natural healing process in the heart.

Pete Hagerstrom, a 73-year-old from Colorado Springs who had a previous quadruple bypass to treat his heart failure, was the first patient in his state enrolled in the ongoing USFDA-approved clinical study of the therapy.Participants who qualify for the study are randomly placed into a treatment group or a control group. While Mr. Hagerstrom will not know until the end of the study if he received the cell therapy, he feels better after participating in the trial.

"Everything is easier. I can walk three miles in about 45 minutes, and it takes a lot less time to garden and shovel snow."The CardiAMP Heart Failure Trial will include up to 260 patients at 40 medical centers nationwide.Unlike similar studies, this trial tests a patient’s bone marrow before treatment, in order to identify those patients who are most likely to benefit from treatment. Patients may be candidates for the CardiAMP Heart Failure Trial if they have heart failure as a result of an earlier heart attack and have symptoms that are classified as New York Heart Association Class II or III.

Tags : #HeartPatients #LatestResearchonHeartFailureTreatment14thDec #LatestPharmaNews14thDec #BoneMarrowTreatment #CardiAMPCellTherapy #COVID-19Pandemic

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024